Introduction {#s1}
============

Oocyte maturation and ovulation are critical steps in the completion of female gametogenesis in the ovary and thus for subsequent fertilization and embryogenesis ([@bib38]). Meiosis in animal oocytes is arrested at prophase of the first division (ProI). Hormonal stimulation triggers the resumption of meiosis in most vertebrates and invertebrates, and oocytes undergo nuclear maturation upon the onset of nuclear disassembly (i.e., germinal vesicle breakdown \[GVBD\]). Concomitant with the progression of nuclear maturation, dynamic rearrangement of intracellular organelles promotes cytoplasmic maturation. Mature oocytes become fertilizable, and their meiosis is arrested again at a species-specific stage: metaphase of the first division (MetI, many invertebrates), metaphase of the second division (MetII, most vertebrates), or G1-phase (some echinoderms and coelenterates) until fertilization. ([@bib52]; [@bib9]; [@bib44]; [@bib17]; [@bib31]; [@bib76]). Mature oocytes are then ovulated via proteolytic degradation of the follicle walls ([@bib53]; [@bib70]; [@bib54]). Some mutations in oocytes lead to infertility in the mature organism, whereas others, over a long period of time, may eventually lead to the emergence of novel species or subspecies. Therefore, the regulatory mechanisms underlying oocyte maturation and ovulation control not only the reproduction of the respective organisms but also evolutionary processes across the animal kingdom.

In vertebrates, oocyte maturation and ovulation are regulated by the hypothalamus-pituitary-gonadal axis (HPG axis); gonadotropins from the pituitary stimulate the maturation of follicles in response to hypothalamic peptide hormones, including gonadotropin-releasing hormone ([@bib52]; [@bib9]; [@bib44]; [@bib17]; [@bib31]; [@bib76]; [@bib53]; [@bib70]; [@bib54]). In contrast, neither a pituitary organ nor gonadotropins arose in most species of invertebrates, indicating the presence of HPG axis--independent regulation in these organisms. Some neuropeptides have been shown to induce oocyte maturation and ovulation (or spawning) in several species of invertebrates. The neuropeptide W/RPRPamide in jellyfish directly induces oocyte maturation and spawning ([@bib72]). A relaxin-like peptide stimulates the production of 1-methyladenosine, which directly induces oocyte maturation, followed by ovulation and spawning ([@bib42]). Cubifurin (NGIWYamide) induces oocyte maturation, ovulation, and spawning in the sea cucumber ([@bib25]). These findings demonstrate that various neuropeptides are responsible for triggering oocyte maturation and ovulation in invertebrates, and suggest that oocyte maturation and ovulation and their underlying molecular mechanisms are regulated in both a species-specific and evolutionarily conserved fashion.

Ascidians are invertebrates that belong to the Chordata superphylum as Urochordata, and thus, phylogenetically, they are the closest living relatives of vertebrates ([@bib12]; [@bib13]; [@bib60]; [@bib21]). As such, ascidians are considered crucial model organisms in research into the evolutionary processes underlying chordate reproductive systems. Our previous studies identified a variety of vertebrate prototypic neuropeptides from the neural complex of the cosmopolitan ascidian, *Ciona intestinalis* Type A (*Ciona robusta*) ([@bib27]; [@bib4]), and we revealed the full trajectory of visceral nerves to the ovary ([@bib47]). Moreover, several cognate receptors were shown to be expressed in the ovary ([@bib26]; [@bib59]; [@bib62]; [@bib73]; [@bib64]), and some neuropeptides, such as *Ciona* tachykinin and neurotensin-like peptide 6, were found to participate in regulating pre-GVBD follicle growth ([@bib1]; [@bib2]; [@bib27]). These findings, considered in the context of the lack of a pituitary organ and gonadotropins, strongly suggest that neuropeptides also play vital roles in oocyte maturation and ovulation in *Ciona*.

*Ciona* meiosis is arrested at ProI, resumes under stimulation by an as yet unidentified factor, and is arrested again at MetI after oocyte maturation and ovulation ([@bib74]; [@bib76]). The importance of pH and levels of cAMP and/or Ca^2+^ in *Ciona* GVBD in artificial seawater (ASW) was previously demonstrated ([@bib65]; [@bib66]; [@bib74]; [@bib36]; [@bib37]). In addition, the activities of MAP kinase (MAPK) and maturation promoting factor (MPF), which are prerequisite for oocyte maturation in vertebrates, have been investigated in *Ciona* post-fertilization ([@bib55]; [@bib56]; [@bib57]). However, neither the endogenous factors nor the signaling pathways regulating GVBD and ovulation in *Ciona* have been identified. Furthermore, investigations of oocyte maturation and ovulation in *Ciona* are expected to provide crucial clues for understanding the evolution and diversification of chordate reproductive systems.

In this study, we documented for the first time the process of ovulation in *Ciona* and demonstrated that the essential molecular mechanisms underlying the onset of GVBD and ovulation are regulated by *Ciona* vasopressin family peptide, CiVP.

Results {#s2}
=======

In vitro evaluation of *Ciona* ovulation {#s2-1}
----------------------------------------

In contrast to oocyte maturation, ovulation in *Ciona* has yet to be documented. We therefore observed ovulation in *Ciona* in vitro. Notably, incubating *Ciona* ovaries in ASW for 16 hr resulted in the liberation of numerous follicles ([Figure 1A](#fig1){ref-type="fig"}). Intriguingly, time-lapse imaging revealed that follicle liberation followed the rupture of the outer follicular cell layer ([Figure 1B](#fig1){ref-type="fig"} and [Video 1](#video1){ref-type="video"}), and we therefore defined this phenomenon as *Ciona* ovulation. Moreover, such rupture of outer follicular cells was also observed in an isolated follicle following GVBD ([Figure 1C](#fig1){ref-type="fig"} and [Video 2](#video2){ref-type="video"}). These results demonstrated that both oocyte maturation and ovulation can be studied in vitro using isolated immature/pre-ovulatory follicles. These data also underscored the advantages of using *Ciona* in research examining the molecular mechanism of oocyte maturation and ovulation. Such experiments, however, will require more-effective methods for isolating immature/pre-ovulatory follicles.

![In vitro system for evaluating *Ciona* oocyte maturation and ovulation.\
(**A**) A *Ciona* ovary was cut into half and incubated in ASW. Numerous follicles were released from the ovary after 16 hr of incubation. (**B**) Time-lapse images of the red-boxed area in (**A**) at the indicated time. The rupturing of the outer follicular cell layer led to follicle release. (**C**) Time-lapse images of an isolated immature/pre-ovulatory (stage III) follicle at the indicated times (upper) and corresponding schematic drawings (lower). Oocyte maturation was observed with germinal vesicle (black arrow) breakdown, and the outer follicular cell layer was ruptured and shrank after ovulation (white arrow). Scale bars are shown for the indicated length.](elife-49062-fig1){#fig1}

###### In vitro ovulation of a *Ciona* ovary.

An isolated *Ciona* ovary was cut in half and incubated in ASW for 16 hr. Time-lapse images were captured every 5 min. Numerous follicles were in turns ovulated from the ovary. The higher-magnification movie of the boxed area indicates that the rupturing of the outer follicular cell layer leads to follicle release.

10.7554/eLife.49062.003

###### In vitro oocyte maturation and ovulation of a *Ciona* follicle.

An immature/pre-ovulatory (stage III) follicle was incubated in ASW for 3 hr. Time-lapse images were captured every 20 s. The follicle structure is illustrated at the right. After germinal vesicle breakdown (GVBD) occurred, the outer follicular cell layer was ruptured, and the follicle was released into ASW, reproducing the ovulation observed in the ovary ([Video 1](#video1){ref-type="video"}).

10.7554/eLife.49062.004

Fractionation of *Ciona* follicles and whole-transcriptome analysis {#s2-2}
-------------------------------------------------------------------

In the *Ciona* ovary, follicles undergo the following major developmental stages: stage I (pre-vitellogenic), stage II (vitellogenic), stage III (post-vitellogenic and pre-GVBD), and stage IV (post-GVBD, that is, mature) oocytes ([@bib50]; [@bib74]; [@bib65]). We fractionated *Ciona* follicles using stainless steel sieves of varying particle sizes. Each fraction collected (20, 38, 63, 90, or 150 μm) contained a major developmental stage of *Ciona* follicles ([@bib50]), namely (i) early stage I, (ii) late stage I to early stage II, (iii) early stage II to late stage II, (iv) late stage II to late stage III, or (v) stage IV oocytes, confirming that the all developmental stages were successfully fractionated ([Figure 2A](#fig2){ref-type="fig"}). RNA-seq analysis of two sets of the fractionated follicles indicated no stage to stage changes in the expression of most genes; however, some differential expression of genes was detected between two consecutive stages ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}), suggesting the usefulness of this approach for identifying genes responsible for oocyte maturation and ovulation. The resultant reads, mapping rate to the *Ciona* cDNA library, and fastq accession numbers in the NCBI SRA database are listed in [Table 1](#table1){ref-type="table"}.

![Fractionation of *Ciona* follicles.\
(**A**) Isolated follicles were fractionated using stainless steel sieves of varying particle sizes (20, 38, 63, 90, or 150 μm). Each fraction contained respective stage of *Ciona* follicles corresponding to (**i**) early stage I, (ii) late stage I to early stage II, (iii) early stage II to late stage II, (iv) late stage II to late stage III, or (**v**) stage IV oocytes. (**B**) Immature/pre-ovulatory follicles were further divided into three groups as indicated, and representative follicles are shown before and after a 24 hr incubation. Scale bars in (**A**) and (**B**) represent 20 and 100 μm. (**C**) Size, GVBD rate, and ovulation rate of late stage II (n = 145), early stage III (n = 100), and late stage III (n = 99) follicles are shown as mean ± SEM.](elife-49062-fig2){#fig2}

10.7554/eLife.49062.009

###### RNA-seq analysis of fractionated *Ciona* follicles.

  Sample                            Total reads   \% Mapped   Accession no.
  --------------------------------- ------------- ----------- ---------------
  **Set 1**                                                   
  early stage I                     22,071,592    65.72       SRR8374812
  late stage I -- early stage II    21,118,716    90.90       SRR8374811
  early stage II -- late stage II   23,935,632    84.31       SRR8374810
  late stage II -- late stage III   23,839,575    50.50       SRR8374809
  stage IV                          22,398,645    32.02       SRR8374816
  **Set 2**                                                   
  early stage I                     22,317,382    45.99       SRR8374815
  late stage I -- early stage II    24,094,643    88.73       SRR8374814
  early stage II -- late stage II   21,434,672    60.23       SRR8374813
  late stage II -- late stage III   20,686,040    43.45       SRR8374808
  stage IV                          23,730,547    31.13       SRR8374807

The immature/pre-ovulatory follicles were then divided into three groups, and the correlation between follicle stage (size) and GBVD or ovulation rate was investigated in detail after a 24 hr incubation. Small follicles (192.1 ± 9.3 μm) exhibited 12.5 ± 4.6% GVBD and 28.6 ± 4.3% ovulation. Such low rates suggested that the follicles were not yet affected by endogenous regulators (e.g., gonadotropins in vertebrates), and thus, they were categorized as 'late stage II' ([Figure 2B and C](#fig2){ref-type="fig"}) based on the results of a previous investigation ([@bib50]). In contrast, mid-size (214.3 ± 7.6 μm) and large (228.8 ± 7.0 μm) follicles exhibited 63.9 ± 8.6% and 91.8 ± 3.4% GVBD, respectively, and 61.4 ± 10.8% and 87.2 ± 1.5% ovulation, respectively, leading to their further respective categorization as 'early stage III' and 'late stage III' ([Figure 2B and C](#fig2){ref-type="fig"}). These late stage II, early stage III, and late stage III follicles were utilized in subsequent experiments.

CiVP and CiErk1/2 promote both GVBD and ovulation {#s2-3}
-------------------------------------------------

Expression of the appropriate receptor genes in immature/pre-ovulatory follicles is a prerequisite for the peptidergic regulation of oocyte maturation and ovulation. Among the several receptors for known *Ciona* neuropeptides in the ovary ([@bib26]; [@bib59]; [@bib62]; [@bib73]; [@bib64]), RNA-seq analysis of fractionated follicles indicated that the expression of only the *CiVpr* gene (KH.C9.885), a receptor for CiVP, was specifically elevated, with peak expression at late stage II to late stage III, a period that is thought to be crucial in the regulation of oocyte maturation and ovulation. This expression profile for the *CiVpr* gene was confirmed by qRT-PCR analysis ([Figure 2---figure supplement 2A,B](#fig2s2){ref-type="fig"}, and [Figure 2---figure supplement 2---source data 1](#fig2s2sdata1){ref-type="supplementary-material"}). These results suggested that CiVP plays important roles in oocyte maturation and ovulation.

*Ciona* follicles are comprised of three types of cells: oocytes, test cells, and follicular cells, and in situ hybridization showed that *CiVpr* mRNA was localized to the oocytes of late stage II follicles ([Figure 3A](#fig3){ref-type="fig"}), in agreement with the results of RNA-seq and qRT-PCR analyses ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"} and [Figure 2---figure supplement 2---source data 1](#fig2s2sdata1){ref-type="supplementary-material"}). These results indicated that CiVP acts on oocytes of late stage II follicles. Consequently, we evaluated the effect of CiVP on GVBD and ovulation. Of particular significance was the finding that treating late stage II follicles with CiVP for 24 hr markedly enhanced both GVBD (39.5 ± 4.2% to 66.2 ± 4.2%) and ovulation (24.8 ± 3.7% to 72.1 ± 5.7%) compared with the control follicles ([Figure 3B,C](#fig3){ref-type="fig"}, [Video 3](#video3){ref-type="video"}, and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Such enhancement was not observed in the presence of inactive linear CiVP in which the cysteine residues are protected with *N*-ethylmaleimide, demonstrating the specificity of CiVP ([Figure 3B and C](#fig3){ref-type="fig"}). Moreover, CiVP-treated oocytes were competent for fertilization and embryonic development ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"} and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}), confirming that the oocytes were actually mature. Collectively, these results indicate that CiVP plays important roles in *Ciona* oocyte maturation and ovulation, which led us to further investigate the underlying molecular mechanisms.

![CiVP and CiErk1/2 promote both GVBD and ovulation.\
(**A**) In situ hybridization using sense strand (SS) or antisense strand (AS) DIG-labeled probes and an NBT/BCIP system for visualizing *CiVpr* indicated its localization in late stage II oocytes (**O**). Enlarged images of red-boxed areas in the upper panels are shown below. (**B**) Representative images of follicles before and after treatment with CiVP for 24 hr. GVBD and ovulation of late stage II follicles were enhanced in the presence of 5 μM CiVP (*t*-value: −4.19; \*\*, p=1.84E-03 in GVBD and *t*-value: −6.97; \*\*, p=3.85E-05 in ovulation), whereas not in the presence of 5 μM inactive linear CiVP (*t*-value: −1.94; p=0.081 in GVBD and *t*-value: −0.27; p=0.79 in ovulation). (**C**) GVBD and ovulation rates were calculated from six independent experiments (n = 6; approximately 20 follicles per experiment) and found to be significantly upregulated in CiVP-treated follicles, indicating that CiVP promotes both oocyte maturation and ovulation. Data were analyzed by Student's *t* test and are shown as mean ± SEM with data points. (**D**) In situ hybridization for *CiErk1/2* indicated its localization in oocytes (**O**) and test cells (Tc). (**E**) Spontaneous GVBD and ovulation of early stage III follicles were inhibited in the presence of 10 μM U0126, an MEK inhibitor. (**F**) GVBD and ovulation rates from four independent experiments (n = 4) indicated that CiErk1/2 regulates both oocyte maturation (*t*-value: 8.72; \*\*, p=1.26E-04) and ovulation (*t*-value: 6.52; \*\*, p=6.22E-04). Data were analyzed and are shown as in (**C**). White arrows (**B, E**) indicate outer follicular cells remaining alongside the follicle. Scale bars in (**A, D**) and (**B, E**) represent 50 and 100 μm, respectively.\
10.7554/eLife.49062.012Figure 3---source data 1.Source data for [Figure 3C,F](#fig3){ref-type="fig"}, and [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}.Percentages of GVBD and ovulated follicles after incubating with CiVP ([Figure 3C](#fig3){ref-type="fig"}) or a MEK inhibitor, U0126 ([Figure 3F](#fig3){ref-type="fig"}). Percentage of immature follicle or developed embryo incubated after in vitro fertilization using CiVP-induced follicles ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}).](elife-49062-fig3){#fig3}

###### CiVP induces *Ciona* GVBD and ovulation.

Isolated late stage II follicles were incubated with (right) or without (left) 5 μM CiVP for 24 hr. Time-lapse images were captured every 5 min. GVBD and ovulation were observed in the CiVP-treated follicle, whereas not in the control follicle.

10.7554/eLife.49062.013

In mammals, the extracellular signal-related kinase (ERK) and MAPK/ERK kinase (MEK) signaling pathways are activated by VP ([@bib34]; [@bib7]), and ERK plays a role in oocyte maturation in vertebrates ([@bib52]; [@bib9]; [@bib17]; [@bib63]). We found that the expression of *CiErk1/2* (KH.L153.20) was elevated throughout follicle development ([Figure 2---figure supplement 2C](#fig2s2){ref-type="fig"} and [Figure 2---figure supplement 2---source data 1](#fig2s2sdata1){ref-type="supplementary-material"}) and localized to oocytes and test cells during most stages, including the identical stage in *CiVpr*-expressing oocytes ([Figure 3D](#fig3){ref-type="fig"}). We then examined the functional relationship between CiErk1/2 and spontaneous oocyte maturation/ovulation. Inhibition of MEK/ERK activity in early stage III follicles using the MEK inhibitor U0126 resulted in significant decreases in the rates of both GVBD (86.2 ± 3.1% to 20.5 ± 9.0%) and ovulation (54.3 ± 5.8% to 6.4 ± 4.5%, [Figure 3E,F](#fig3){ref-type="fig"}, [Video 4](#video4){ref-type="video"}, and [Figure 3---source data 1](#fig3sdata1){ref-type="supplementary-material"}). Collectively, these results indicated that CiErk1/2 plays crucial roles in both oocyte maturation and ovulation and further suggest that CiVP signaling is mediated by CiErk1/2.

###### The MEK inhibitor U0126 inhibits *Ciona* GVBD and ovulation.

Isolated early stage III follicles were incubated with (right) or without (left) 10 μM U0126 for 24 hr. Time-lapse images were captured every 5 min. GVBD and ovulation were observed in the control follicle, whereas those were inhibited in the U0126-treated follicle.

10.7554/eLife.49062.014

CiVP promotes GVBD via the ERK-MPF pathway {#s2-4}
------------------------------------------

Subsequently, we examined whether CiErk1/2 is phosphorylated upon CiVP stimulation. Western blotting and immunofluorescence analyses confirmed both the specificity of the anti--phosphorylated ERK1/2 (pERK1/2) antibody ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}) and the previously reported inhibitory effect of U0126 on native CiErk1/2 phosphorylation in *Ciona* embryos ([@bib10]; [@bib6]; [@bib22]; [@bib49]). Immunofluorescence analysis of de-folliculated oocytes revealed extensive phosphorylation of CiErk1/2 at 5--10 min after CiVP stimulation, whereas no induction was observed in MEK-inhibited follicles ([Figure 4A](#fig4){ref-type="fig"}). RNA-seq analysis was employed to examine the expression of downstream factors of MEK/ERK signaling in oocyte maturation and ovulation using three sets of MEK-inhibited early stage III follicles ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, [Supplementary file 2](#supp2){ref-type="supplementary-material"}, and [Table 2](#table2){ref-type="table"}). We focused on the two major MPF components, cyclin B (CcnB) and Cdc2 (Cdk1), given that oocyte maturation is triggered by activation of MPF in a wide variety of both vertebrates and invertebrates ([@bib52]; [@bib44]; [@bib31]; [@bib9]; [@bib17]). BLAST analyses using the *Ciona* protein database identified the *Ciona* cyclin B (*CiCcnb*, KH.C4.213) and *Ciona* Cdc2 (also known as Cdk1, *CiCdk1*, KH.C12.372) genes. The RNA-seq data revealed no significant changes in the expression of *CiCdk1* or *CiCcnb* in MEK-inhibited follicles ([Figure 4---figure supplement 3A](#fig4s3){ref-type="fig"} and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}), suggesting that MPF is regulated post-translationally in *Ciona*, as in other animals ([@bib52]; [@bib44]; [@bib31]; [@bib9]; [@bib17]). The selective Cdc2 inhibitor Ro-3306 inhibited GVBD in late stage III follicles ([Figure 4B](#fig4){ref-type="fig"} and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}), confirming that MPF activity is also necessary for GVBD in *Ciona*. The inhibitory effect of Ro-3306 on native MPF (CiCdk1) was confirmed using an in vitro assay ([Figure 4---figure supplement 3B,C](#fig4s3){ref-type="fig"}, and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}). Notably, CiVP-directed GVBD using late stage II follicles was completely blocked by MPF inhibition ([Figure 4C](#fig4){ref-type="fig"} and [Figure 4---source data 1](#fig4sdata1){ref-type="supplementary-material"}), indicating that MPF is required for the induction of GVBD by CiVP. Consequently, these results led to the conclusion that CiVP is a key molecule in the initiation of oocyte maturation via the MEK/ERK-MPF pathway in *Ciona* oocytes.

![CiVP promotes GVBD via CiErk1/2-CiMPF pathway.\
(**A**) Indicated numbers of numbers of de-folliculated oocytes pretreated with or without 10 μM U0126 were stimulated with 5 μM CiVP for 0, 5, 10, 20, 40, and 60 min. Immunofluorescence using anti-phosphorylated ERK1/2 antibody indicated specific activation of CiErk1/2 at 5 to 10 min after CiVP stimulation (*F* = 14.91; p=2.12E-12), which was not observed in control (*F* = 1.05; p=0.39) or U0126-pretreated oocytes (*F* = 2.13; p=0.065). Representative images are shown (left). Signal intensities were quantified using Fiji software (right), and significant activation was verified by one-way factorial ANOVA followed by Tukey's *post hoc* test (\*\*, *P\<*0.01). (**B**) Treatment with 1 μM Ro-3306, a selective Cdc2 inhibitor, significantly inhibited GVBD in late stage III follicles (*t*-value: 9.12; \*\*, p=3.67E-06). (**C**) CiVP-induced GVBD of late stage II follicles (*t*-value: −2.83; \*, p=0.047) was disrupted by Ro-3306 (*t*-value: 4.12; \*, p=0.015). Representative images of follicles and GVBD rates are shown. Data from six (B, n = 6) and three (C, n = 3) independent experiments were analyzed by Student's *t* test and are shown as mean ± SEM with data points.\
10.7554/eLife.49062.019Figure 4---source data 1.Source data for [Figure 4B,C](#fig4){ref-type="fig"}, [Figure 4---figure supplement 3A and C](#fig4s3){ref-type="fig"}.Percentages of GVBD follicles after incubating with CiVP and/or a Cdc2 inhibitor, Ro-3306 ([Figure 4B and C](#fig4){ref-type="fig"}). Relative expression values of the *CiCcnb* and *CiCdk1* genes to *CiUbac1* (RNA-seq data, [Figure 4---figure supplement 3A](#fig4s3){ref-type="fig"}) and relative values of in vitro CiCdk1 activity are also shown ([Figure 4---figure supplement 3C](#fig4s3){ref-type="fig"}).](elife-49062-fig4){#fig4}

10.7554/eLife.49062.020

###### RNA-seq analysis of MEK-inhibited follicles

  Sample      Total reads   \% Mapped   Accession no.
  ----------- ------------- ----------- ---------------
  **Set 1**                             
  Control     32,160,880    74.49       SRR8375763
  U0126       24,928,350    74.46       SRR8375762
  **Set 2**                             
  Control     32,642,355    72.66       SRR8375761
  U0126       32,197,268    64.87       SRR8375760
  **Set 3**                             
  Control     32,136,047    58.70       SRR8375759
  U0126       25,912,488    60.77       SRR8375758

CiVP activates CiMMP2/9/13 via MEK/ERK signaling prior to ovulation {#s2-5}
-------------------------------------------------------------------

In medaka, a teleost fish species, three MMPs (MMP-2, MMP-14, MMP-15) have been identified as essential enzymes for ovulation ([@bib45]), but no proteases have been identified as essential for mammalian ovulation. In *Ciona*, six MMP-like genes were annotated with KH accession information in the *Ciona* gene database ([@bib29]), and thus, the expression profiles of these genes were examined using the present RNA-seq data ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}) for early stage III follicles in which ovulation was inhibited with an MEK inhibitor. Of these six genes, the expression of only *CiMmp2/9/13* (KH.L76.4) declined by approximately 80% in MEK-inhibited follicles compared with the control ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). The results of qRT-PCR analysis using MEK-inhibited follicles also revealed a significant 70% decrease in *CiMmp2/9/13* mRNA levels ([Figure 5A](#fig5){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Notably, CiVP stimulation of late stage II follicles resulted in a 4.0-fold upregulation of *CiMmp2/9/13* expression ([Figure 5B](#fig5){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}), confirming that CiVP induces *CiMmp2/9/13* expression via MEK/ERK signaling during ovulation. This led us to further investigate the functional roles of CiMMP2/9/13 protein in *Ciona* ovulation.

![CiVP activates CiMMP2/9/13 via MEK/ERK signaling during ovulation.\
(**A, B**) qRT-PCR indicated that MEK inhibition with 10 μM U0126 in early stage III follicles (**A**) and 5 μM CiVP stimulation in late stage II follicles (**B**) for 24 hr results in decrease and increase of *CiMmp2/9/13* expression relative to *CiUbac1*, respectively. Data from three (A, n = 3) and six (B, n = 6) independent experiments were analyzed by Student's *t* test and are shown as mean ± SEM with data points (*t*-value: 3.08; \*, p=0.037 in (**A**) and *t*-value: −3.24; \*\*, p=8.92E-03 in (**B**)). (**C**) Immunohistochemistry using anti-CiMMP2/9/13 antiserum and the ABC detection system confirmed that CiMMP2/9/13 is localized in oocytes (**O**) and outer follicular cells (OFc), but not in test cells (Tc). Antiserum pre-absorbed with antigen or pre-immune serum (inset) were used as negative controls. Enlarged images of red-boxed areas in the upper panels are shown below. (**D**) Treatment with 20 μM MMP-2/9 inhibitor II significantly inhibited ovulation of late stage III follicles (*t*-value: 8.14; \*\*, p=1.24E-03). (**E**) Significant CiVP-induced ovulation of late stage II follicles (*t*-value: −6.38; \*\*, p=2.13E-04) was disrupted by MMP-2/9 inhibitor II (*t*-value: 10.25; \*\*, p=7.07E-06). Data from three (D, n = 3) and five (E, n = 5) independent experiments were analyzed by Student's *t* test and are shown as mean ± SEM with data points.\
10.7554/eLife.49062.025Figure 5---source data 1.Source data for [Figure 5A,B,D,E](#fig5){ref-type="fig"}, [Figure 5---figure supplements 1](#fig5s1){ref-type="fig"} and [3](#fig5s3){ref-type="fig"}.Relative expression values of the *CiMmp2/9/13* gene to *CiUbac1* (RNA-seq and qRT-PCR data, [Figure 5A and B](#fig5){ref-type="fig"}). Percentages of ovulated follicles after incubating with CiVP and/or MMP-2/9 inhibitor II ([Figure 5D and E](#fig5){ref-type="fig"}). Relative expression values of the *CiMmp* genes to *CiUbac1* (RNA-seq data, [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Raw values of in vitro collagenase activity of recombinant MMP-2/9/13 are also shown ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}).](elife-49062-fig5){#fig5}

We generated an anti-CiMMP2/9/13 antibody using the active form of recombinant CiMMP2/9/13 (rCiMMP2/9/13), and the antibody's specificity was confirmed by Western blotting analysis ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). Immunohistochemistry analysis revealed that CiMMP2/9/13 protein localized in oocytes and the outer follicular cell layer of late stage III follicles ([Figure 5C](#fig5){ref-type="fig"}), and this result was in good agreement with the localization of CiVPR ([Figure 3A](#fig3){ref-type="fig"}) and CiErk1/2 ([Figure 3D](#fig3){ref-type="fig"}). Subsequently, we treated late stage III follicles with MMP-2/9 inhibitor II. As expected, inhibition of CiMMP2/9/13 resulted in a significant decrease in the ovulation rate (91.5 ± 3.2% to 41.4 ± 3.1%), compared with uninhibited follicles ([Figure 5D](#fig5){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). It is noteworthy that CiVP-induced ovulation via upregulation of CiMMP2/9/13 in late stage II follicles was completely blocked by MMP-2/9 inhibitor II ([Figure 5E](#fig5){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}). Collectively, these results indicated that CiMMP2/9/13 expression is induced by CiVP via CiErk1/2 in oocytes and plays a pivotal role in *Ciona* ovulation.

CiMMP2/9/13 digests both collagen type I and type IV around the outer follicular cell layer {#s2-6}
-------------------------------------------------------------------------------------------

MMPs digest extracellular matrix components, including collagens ([@bib39]), and our current data support the hypothesis that CiMMP2/9/13 digests collagen type I and type IV in *Ciona* follicles during ovulation. Incubation of rCiMMP2/9/13 with putative substrates DQ collagen (fluorescent dye and its quencher are conjugated) type I or type IV in vitro resulted in significant digestion of these collagens, but collagen digestion was inhibited by MMP-2/9 inhibitor II. These results confirmed the enzymatic activity of CiMMP2/9/13 and the usefulness of its inhibitor ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"} and [Figure 5---source data 1](#fig5sdata1){ref-type="supplementary-material"}).

Next, we performed in situ zymography analysis to determine the localization of CiMMP2/9/13 activity within *Ciona* follicles during and after ovulation. While no activity was observed in oocytes, test cells, and follicular cells in ovulating follicles, potent collagenase activity was observed in the outer follicular cell layer in the presence of DQ collagen type I or type IV ([Figure 6](#fig6){ref-type="fig"}). Intriguingly, the outer follicular layer of post-ovulatory follicles also exhibited high activity toward collagen type I and type IV. Collectively, these results led to the conclusion that CiVP induces CiMMP2/9/13 expression via CiVPR-MEK/ERK signaling in oocytes and that secreted CiMMP2/9/13 digests collagens type I and type IV in the outer follicular cell layer, which causes the follicle to rupture, with subsequent liberation of oocytes from the ovary (i.e., ovulation).

![Collagenase activity is localized to the outer follicular cells.\
Ovulating follicles and outer follicular cells of post-ovulatory follicles were incubated for 3 hr in the presence of 50 μg/ml of DQ-collagen type I or type IV. In situ zymography indicated that the collagenase activity was localized to the outer follicular cells of ovulating follicles (upper, arrowheads) and post-ovulatory follicles (lower). No signals were observed in the follicles incubated without DQ-substrates.](elife-49062-fig6){#fig6}

Discussion {#s3}
==========

Oocyte maturation and ovulation are regulated by the HPG axis in vertebrates, whereas most invertebrates do not have an HPG axis. Hence, invertebrate reproductive processes are regulated by HPG axis--independent systems, but many details of the underlying molecular mechanisms of these systems remain to be elucidated. Over the past decade, some neuropeptides were found to play key roles in oocyte maturation and ovulation (or spawning) in a limited number of invertebrates, such as jellyfish (W/RPRPamide, [@bib72]), starfish (relaxin-like peptide, [@bib42]), and sea cucumber (cubifrin: NGIWYamide, [@bib25]). In contrast, no endogenous factors involved in the regulation of oocyte maturation or ovulation have been identified in ascidians. This has hampered investigations into the molecular mechanisms underlying the reproductive system in the closest sister group to vertebrates and the evolution and diversification of the oocyte maturation and ovulation systems in chordates. Using original assays for examining ovulation in *Ciona* follicles ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}) in the present study, we demonstrated that essential systems in oocyte maturation and ovulation in the ascidian *Ciona intestinalis* Type A are regulated by the vasopressin/oxytocin (VP/OT) family peptide, CiVP ([Figure 7](#fig7){ref-type="fig"}).

![Model describing the regulation of CiVP-directed oocyte maturation and ovulation.\
(**A**) Schematic diagram of the *Ciona* ovary, modified from [@bib69]. Mature/ovulated follicles are stored in the oviduct and wait for spawning stimulation. Yellow and blue represent inside and outside of the ovary, respectively. (**B**) Enlarged structure of ovulating follicle indicated by the red box in (**A**), modified from [@bib30]. (**C**) Enlarged illustration of the red box in (**B**) and regulatory mechanisms of the CiVP-directed *Ciona* oocyte maturation and ovulation. CiVP interacts with its receptor expressed in the oocyte and directly activates MEK/CiErk1/2 signaling. Subsequent activation of CiMPF leads to GVBD and oocyte maturation. Activated CiErk1/2 also induces the CiMMP2/9/13 expression in the oocyte; secreted CiMMP2/9/13 then digests collagens in the outer follicular cell layer, leading to the rupture of the follicular layer and ovulation.](elife-49062-fig7){#fig7}

One of the greatest difficulties in studies of oocyte maturation and ovulation involves the isolation and fractionation of vital follicles and oocytes at each developmental stage. In this study, we established a method for culturing and fractionating vital *Ciona* follicles across all developmental stages using stainless steel sieves of varying particle sizes ([Figure 2A](#fig2){ref-type="fig"}). This method enabled both the first observation of *Ciona* ovulation ([Figure 1C](#fig1){ref-type="fig"} and [Video 2](#video2){ref-type="video"}) and exploration of the molecular mechanisms underlying oocyte maturation and ovulation ([Figures 3](#fig3){ref-type="fig"}--[7](#fig7){ref-type="fig"}). Such fractionation and culture systems are likely to be applicable to other organisms and thus should encourage studies of oocyte maturation and ovulation in various species. Moreover, transcriptomic data covering all developmental stages of *Ciona* follicles ([Figure 2A](#fig2){ref-type="fig"}, [Figure 2A---figure supplement 1](#fig2s1){ref-type="fig"}, and [Supplementary file 1](#supp1){ref-type="supplementary-material"}) will contribute to the comprehensive understanding of not only oocyte maturation and ovulation but also the entire mechanism of *Ciona* follicle development.

The vertebrate OT and VP families are thought to have emerged from a common ancestral gene via gene duplication during the evolution of gnathostomates, and invertebrates and jawless vertebrates have been shown to possess a single VP/OT family peptide ([@bib3]; [@bib68]; [@bib14]). Furthermore, the involvement of VP/OT family peptides in various reproduction-related functions has been documented. The earthworm VP/OT family peptide annetocin and nematode VP/OT family peptide nematocin induce egg-laying behavior ([@bib18]; [@bib48]; [@bib58]; [@bib19]). Vasotocin (VT), a non-mammalian vertebrate VP family peptide exhibited similar functions in amphibians ([@bib43]), and its involvement in spawning migration in fish and ovipositioning in birds was also suggested, although the underlying molecular mechanisms remain to be investigated. VT was also reported to be involved in oocyte maturation and ovulation in catfish ([@bib67]; [@bib23]). However, VT-induced oocyte maturation and ovulation are mediated primarily via the VT receptor in follicular cells and following sexual steroidogenesis ([@bib67]; [@bib23]; [@bib51]). This is distinct from the present data indicating that CiVP directly acts on CiVPR expressed in oocytes to induce oocyte maturation and ovulation without steroidogenesis. This is also consistent with the complete absence of major steroidogenesis genes in the *Ciona* genome ([@bib11]). Collectively, these findings suggest that VT and CiVP participate in oocyte maturation and ovulation via distinct molecular mechanisms in catfish and *Ciona*, respectively. In other words, the biological role of VP family peptides in oocyte maturation and ovulation might have been acquired at least by common ancestors of Olfactores (vertebrates and urochordates) and conserved in both *Ciona* and fish, with diversification of the molecular mechanisms in species-specific evolutionary lineages. In mammals, the murine VP-receptor genes *Avpr1a* and *1b* and OT-receptor gene *Oxtr* are reportedly expressed in the ovary (MGI Direct Data Submission MGI:3625434, MGI:3625077, MGI:5895306, and SRS307248). However, no effects of deficiencies of these genes on oocyte maturation and ovulation in mice have been reported ([@bib33]; [@bib71]). Taken together, these results suggest that the biological roles of VPergic oocyte maturation and ovulation might have been lost or replaced by other factors in mammals. Consequently, elucidating the biological roles of VP/OT family peptides in the ovary and in the process of VPergic oocyte maturation and ovulation evolution awaits further investigations.

Oocyte maturation (GVBD) in vertebrates (meiotic resumption from ProI to MetII via GVBD) is regulated in follicles by sex steroids and subsequently by several signaling cascades, including the Mos-MAPK and MPF pathways ([@bib52]; [@bib9]; [@bib44]; [@bib17]). In ascidians, MAPK and MPF activity function after fertilization, given that *Ciona* oocytes are re-arrested at MetI after GVBD and resume meiosis in response to fertilization ([@bib55]; [@bib56]; [@bib57]; [@bib15]). However, the functional roles of MAPK and MPF at the onset of *Ciona* GVBD and the identity of their upstream regulator remain unclear. We demonstrated that CiErk1/2 is directly phosphorylated by CiVP in the oocytes ([Figure 4A](#fig4){ref-type="fig"}) and that MEK inhibition prevents spontaneous GVBD of early stage III follicles ([Figure 3E and F](#fig3){ref-type="fig"}), in contrast to a previous study ([@bib36]). This discrepancy is likely the result of the involvement of CiErk1/2 in GVBD of *Ciona* oocytes over a limited period; CiErk1/2 is triggered around early stage III; subsequent MEK inhibition during late stage III is no longer able to prevent spontaneous GVBD. Although CiErk1/2 is expressed both in oocytes and test cells ([Figure 3D](#fig3){ref-type="fig"}), de-folliculated *Ciona* oocytes are competent for GVBD ([@bib65]), supporting the hypothesis that CiErk1/2 in oocytes (rather than in test cells) is important for *Ciona* GVBD, as reported in *Xenopus* ([@bib32]; [@bib8]; [@bib17]). Moreover, we verified that spontaneous GVBD of late stage III follicle is disrupted by inhibition of a major component of MPF, Cdc2, indicating that MPF activity is responsible for *Ciona* GVBD, as reported in vertebrates ([@bib9]; [@bib44]), starfish ([@bib31]), fruit flies ([@bib75]; [@bib20]), and nematodes ([@bib5]). In addition, we demonstrated that CiVP-induced GVBD is completely blocked by MPF (Cdc2) inhibition ([Figure 4C](#fig4){ref-type="fig"}), which is consistent with the observation that the triggering factors of oocyte maturation (e.g., maturation-inducing hormone) are highly variable among species ([@bib72]; [@bib31]; [@bib44]). Collectively, the current results provide evidence that CiVP triggers *Ciona* nuclear maturation of oocytes via the MEK/ERK-MPF pathway, which appears to be highly conserved among some vertebrates. Additionally, in vitro fertilization experiments using follicles in which maturation was induced by CiVP showed incomplete development of some follicles ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), suggesting the involvement of other factors in nuclear or cytoplasmic maturation of oocytes. However, the present study provides new evidence identifying CiVP as the only VP/OT family peptide that plays a crucial role in initiating GVBD via the MEK/ERK-MPF pathway in a chordate. Thus, how VP was replaced by other factors in MEK/ERK-MPF--directed GVBD in vertebrates is of particular interest.

Neither ovulation itself nor its mechanism have been documented in *Ciona*. We verified that the VPergic ovulation process involves CiVP-mediated upregulation of CiMMP2/9/13 via CiErk1/2 activation, in turn leading to the degradation of collagens followed by the release of oocytes from the ovary ([Figures 3](#fig3){ref-type="fig"}, [4A](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). This is in good agreement with the results of previous studies of medaka demonstrating that MMP-2 and MMP-15 are responsible for the respective degradation of type IV and type I collagens and ovulation ([@bib45]; [@bib70]), although medaka MMP-15 is induced by sex steroids ([@bib46]) and no role for medaka ERK in ovulation has been demonstrated. In contrast, conditional ERK1/2-deficient mice lack ovulated oocytes ([@bib16]), and critical proteases have yet to be identified. Consequently, the present study provides the first demonstration of the biological roles of VP family peptides in regulating ovulation and inducing MMP via ERK in chordates ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}).

Considered along with the aforementioned involvement of MMPs in ovulation in vertebrates, the present data regarding the MEK/ERK-MMP regulatory pathway in *Ciona* ovulation suggest the following three-step evolutionary process: i) common chordate ancestors might have adopted the MEK/ERK-MMP pathway, which is also conserved in *Ciona* ovulation; ii) MEK/ERK regulation in fish might have been lost or compensated by other regulators, given that an MEK/ERK-directed ovulatory mechanism has been demonstrated in mammals; and iii) the roles of various proteases, including MMPs, in vertebrate ovulatory regulation have diversified during the evolutionary process ([Figure 7---figure supplement 1i-iii](#fig7s1){ref-type="fig"}). Although the evolutionary conservation and detailed mechanism of ovulatory regulation via the MEK/ERK-MMP pathway in chordates await further investigation, the results of the present study suggest that VP/OT family peptide--directed regulation of oocyte maturation and ovulation might have originated in ancestral chordates and that other regulators, including sex steroids, prostaglandins, and gonadotropins, diverged along with the evolution of vertebrates.

In conclusion, the present study provides evidence that CiVP triggers oocyte maturation and ovulation via MEK/ERK signaling followed by MPF- and CiMMP2/9/13-directed collagen degradation, respectively, in the closest sister group of vertebrates. These data suggest that VP/OT family peptides have played key roles in the evolution of regulatory mechanisms underlying oocyte maturation and ovulation in chordates.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                    Designation                          Source or reference                                                                  Identifiers                                                    Additional\
  (species) or resource                                                                                                                                                                                                                     information
  ------------------------------------------------ ------------------------------------ ------------------------------------------------------------------------------------ -------------------------------------------------------------- --------------------------------------------------------------
  Gene (*Ciona intestinalis* type A)               *CiVp*                               *Ciona* Ghost Database (<http://ghost.zool.kyoto-u.ac.jp/cgi-bin/gb2/gbrowse/kh/>)   KH.C6.11.                                                      

  Gene (*Ciona intestinalis* type A)               *CiVpr*                              *Ciona* Ghost Database (<http://ghost.zool.kyoto-u.ac.jp/cgi-bin/gb2/gbrowse/kh/>)   KH.C9.885.                                                     

  Gene (*Ciona intestinalis* type A)               *CiErk1/2*                           *Ciona* Ghost Database (<http://ghost.zool.kyoto-u.ac.jp/cgi-bin/gb2/gbrowse/kh/>)   KH.L153.20.                                                    

  Gene (*Ciona intestinalis* type A)               *CiCcnb*                             *Ciona* Ghost Database (<http://ghost.zool.kyoto-u.ac.jp/cgi-bin/gb2/gbrowse/kh/>)   KH.C4.213.                                                     

  Gene (*Ciona intestinalis* type A)               *CiCdk1*                             *Ciona* Ghost Database (<http://ghost.zool.kyoto-u.ac.jp/cgi-bin/gb2/gbrowse/kh/>)   KH.C12.372.                                                    

  Gene (*Ciona intestinalis* type A)               *CiMmp2/9/13*                        *Ciona* Ghost Database (<http://ghost.zool.kyoto-u.ac.jp/cgi-bin/gb2/gbrowse/kh/>)   KH.L76.4.                                                      

  Recombinant DNA reagent                          pET21a-CiMMP2/9/13 (plasmid)         This paper                                                                                                                                          Expression vector of Ci-MMP2/9/13

  Strain, strain background (*Escherichia coli*)   Rossetta 2 (DE3)                     Novagen                                                                              Cat.\#:71400--3                                                Competent cells for rCi-MMP2/9/13 expression

  Antibody                                         anti-ERK\                            Cell Signaling Technology                                                            Cat.\#:9102S;\                                                 WB (1:500)
                                                   (rabbit polyclonal)                                                                                                       RRID:[AB_330744](https://scicrunch.org/resolver/AB_330744)     

  Antibody                                         anti-pERK\                           Cell Signaling Technology                                                            Cat.\#:9101S;\                                                 IF (1:200); WB (1:1000)
                                                   (rabbit polyclonal)                                                                                                       RRID:[AB_331646](https://scicrunch.org/resolver/AB_331646)     

  Antibody                                         anti-PSTAIR\                         Abcam                                                                                Cat.\#:Ab10345;\                                               WB (1:1000)
                                                   (mouse monoclonal)                                                                                                        RRID:[AB_297080](https://scicrunch.org/resolver/AB_297080)     

  Antibody                                         anti-CiMMP2/9/13                     This paper                                                                                                                                          IHC (1:400); WB (1:3000)

  Commercial assay or kit                          MESACUP Cdc2/Cdk1 Kinase Assay kit   MBL                                                                                  Cat.\#:5235                                                    

  Commercial assay or kit                          Universal Elite ABC kit              Vector Laboratories                                                                  Cat.\#:PK-7200                                                 

  Peptide, recombinant protein                     CiVP                                 [@bib26] (PMID: [18586058](https://www.ncbi.nlm.nih.gov/pubmed/18586058))                                                                           5 μM

  Chemical compound, drug                          U0126                                Promega                                                                              Cat.\#:V1121                                                   10 μM

  Chemical compound, drug                          Ro-3306                              Abcam                                                                                Cat.\#:ab141491                                                1 μM

  Chemical compound, drug                          MMP-2/MMP-9 inhibitor II             Calbiochem                                                                           Cat.\#:444249                                                  20 μM

  Chemical compound, drug                          DQ Collagen, type I                  Thermo Fisher Scientific                                                             Cat.\#:D12060                                                  50 μg/ml

  Chemical compound, drug                          DQ Collagen, type IV                 Thermo Fisher Scientific                                                             Cat.\#:D12052                                                  50 μg/ml

  Software, algorithm                              Free-JSTAT statistical software      FreeJSTAT (<http://toukeijstat.web.fc2.com/>)                                                                                                       Version 22.0E

  Software, algorithm                              Fiji software                        Fiji (<http://fiji.sc/>);\                                                           RRID:[SCR_002285](https://scicrunch.org/resolver/SCR_002285)   
                                                                                        [@bib61] (PMID: [22743772](https://www.ncbi.nlm.nih.gov/pubmed/22743772))                                                                           

  Sequence-based reagent                           Primers                              This paper                                                                                                                                          Sequences are listed in [Table 3](#table3){ref-type="table"}
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In vitro oocyte maturation and ovulation of *Ciona* follicles {#s4-1}
-------------------------------------------------------------

Adult *Ciona* were cultivated at the Maizuru Fisheries Research Station of Kyoto University or Misaki Marine Biological Station of the University of Tokyo and maintained in sterile ASW at 18°C. Half pieces of the ovaries or follicles from adult *Ciona* were incubated at 20°C; time-lapse images were captured every 20 s or 5 min over a 3-, 16-, or 24 hr period using a Leica M205 AF stereomicroscope. The *Ciona* ovary includes numerous immature/pre-ovulatory follicles beside the ovarian tube, which leads to the oviduct. Mature oocytes in the ovary are extruded into the ovarian tube (ovulated) and stored in the oviduct until spawning ([Figure 7A and B](#fig7){ref-type="fig"}; [@bib69]; [@bib30]). Oocyte maturation was evaluated as an index of GVBD. Oocyte maturity was examined using an in vitro fertilization assay ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}), the detailed method of which is described below. Ovulation was defined as rupturing of the outer follicular cell layer followed by release of the ovulated follicles. Rates of GVBD and ovulation were calculated 24 hr after incubation in the presence or absence of various chemicals and/or neuropeptides. Follicular size was measured using Fiji software ([@bib61]).

Isolated *Ciona* follicles were fractionated using a series of stainless steel sieves of varying particle sizes (150, 90, 63, 38, and 20 μm). Thousands of follicles were collected from each sieve after washing with an excess amount of ASW. Two independent sets of follicles were used for RNA-seq, and three additional sets were used for qRT-PCR. Immature/pre-ovulatory follicles were further isolated under a stereomicroscope (Discovery V8, Carl Zeiss Microscopy, Tokyo, Japan) and divided into three gropes (late stage II, early stage III, and late stage III) based on size, and GVBD and ovulation rates were determined after a 24 hr incubation. Approximately 20--30 follicles of late stage II, early stage III, or late stage III were randomly allocated and incubated with various chemicals and/or CiVP, and GVBD and ovulation rates were determined after a 24 hr incubation. Synthetic CiVP peptide was prepared as previously described ([@bib26]) and used at a final concentration of 5 μM, given that lower concentrations of other peptides are reportedly ineffective in *Ciona* ([@bib24]). Linear CiVP with the cysteine residues protected by *N*-ethylmaleimide was synthesized under reducing conditions and confirmed using MALDI-TOF mass spectrometry. The MEK inhibitors U0126 (Promega, Tokyo, Japan), Ro-3306 (Abcam, Tokyo, Japan), and MMP-2/MMP-9 inhibitor II (Calbiochem, San Diego, CA) were used at a final concentration of 10 μM, 1 μM, and 20 μM, respectively. The inhibitory effects of these chemicals on *Ciona* enzymes were evaluated using Western blotting ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}), immunofluorescence ([Figure 4A](#fig4){ref-type="fig"}), and activity assays ([Figure 4---figure supplement 3C](#fig4s3){ref-type="fig"} and [Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}). Three independent sets of MEK-inhibited follicles were collected for subsequent RNA-seq analyses, and another three independent sets were used for qRT-PCR assays.

RNA extraction, purification, and RNA-seq analyses {#s4-2}
--------------------------------------------------

Total RNA was extracted from isolated follicles, purified, and treated with TURBO DNase as previously described ([@bib41]). A total of 500 ng or 150 ng of quality-verified RNA from sieved follicles or further purified follicles, respectively, was subjected to RNA-seq analysis using a HiSeq1500 instrument (Illumina, San Diego, CA) in the rapid mode, as previously described ([@bib28]; [@bib35]). The resultant reads were aligned to the *Ciona* cDNA library, which was downloaded from the ghost database (<http://ghost.zool.kyoto-u.ac.jp/cgi-bin/gb2/gbrowse/kh/>). The expression level of each gene was calculated as gene-specific reads per kilobase per million total reads (RPKM). Total reads, mapping rates, and accession numbers are summarized in [Tables 1](#table1){ref-type="table"} and [2](#table2){ref-type="table"}. Scatter plots are shown in [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"} and [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}, and DEG profiles are shown in [Supplementary files 1](#supp1){ref-type="supplementary-material"} and [2](#supp2){ref-type="supplementary-material"}.

qRT-PCR {#s4-3}
-------

A 100 ng aliquot of DNase-treated total RNA isolated from *Ciona* follicles was used for first-strand cDNA synthesis. qRT-PCR was performed using a CFX96 Real-time System and SsoAdvanced Universal SYBR Green Supermix (Bio-Rad laboratories, Hercules, CA), as previously described ([@bib28]). The primers used for qRT-PCR analyses are listed in [Table 3](#table3){ref-type="table"}. Gene expression levels were normalized to the expression of the ubiquitin-associated domain containing one gene (*CiUbac1*, KH.L133.5), which was found to be constitutively expressed throughout follicular development according to the RNA-seq analysis.

10.7554/eLife.49062.029

###### Primer sets used in this study

  Name                 Accession no.   Forward                 Reverse
  -------------------- --------------- ----------------------- -----------------------
  **qRT-PCR**                                                  
  *CiVpr*              KH.C9.885       ATGCACCGTGTCCGAAATG     CAAAGCGACCAGGACACAAG
  *CiErk1/2*           KH.L153.20      TTATGTCTCTGCCGAACAAGC   AAGGTCAGCATACGGTCCAA
  *CiMmp2/9/13*        KH.L76.4        GCTTAATTGGCTGCGATCCA    TCGTCTCCATAGTGACATCGG
  *CiUbac1*            KH.L133.5       ACACGCCGATGATTCAAGTG    GGTGAGTCGGGTTTGGTTTG
  **Probes for ISH**                                           
  *CiVpr*              KH.C9.885       CCTGCAGCGACAAATACGAA    GGAACAACTGTGGTGTGGAC
  *CiErk1/2*           KH.L153.20      TAAGAGCTCCCACACTTGCA    GCATGATTTCGGGAGCTCTG

In situ hybridization cDNA fragments of *CiVpr* (KH.C9.885) and *CiErk1/2* (KH.L153.20) were amplified using cDNA from *Ciona* ovaries and the primers listed in [Table 3](#table3){ref-type="table"}, and the fragments were then inserted into the pCR4-TOPO vector (Thermo Fisher Scientific, Waltham, MA). After the sequences were verified, the vector was linearized using *Not*I or *Pme*I for the synthesis of digoxigenin (DIG)-labeled cRNA probes, as previously described ([@bib27]; [@bib40]). Isolated *Ciona* ovaries were fixed in 4% paraformaldehyde (PFA), embedded in Super Cryo Embedding Medium (SCEM), and sectioned at 10 μm. Sections were treated with 1 μg/ml proteinase K (Nacalai Tesque, Kyoto, Japan) for 1--2 min at room temperature and re-fixed in the same fixative for 10 min. The samples were acetylated with 0.25% acetic anhydride in 0.1 M triethanolamine/HCl (Nacalai Tesque) (pH 8.0) for 10 min. After pre-hybridization for 1 hr at room temperature in buffer A (50% formamide, 6 × SSPE, 5 × Denhardt's solution, and 0.5 mg/ml yeast transfer RNA) or buffer B (50% formamide, 10 mM Tris-HCl, 1 mM EDTA, 0.6 M NaCl, 0.25% SDS, 1 × Denhardt's solution, 0.2 mg/ml yeast transfer RNA \[pH 8.0\]), hybridization was performed at 55--60°C for 16 hr in identical buffer containing 100--200 ng/ml DIG-labeled cRNA probes. The slides were washed three times with 0.2 × SSC at 55--60°C for 20 min each, blocked with 1% blocking reagent (Roche, Basel, Switzerland) in DIG buffer 1 (100 mM maleic acid, 150 mM NaCl \[pH 7.5\]) for 1 hr, and then treated with anti-DIG antibody (Roche, 1:5000) for 30 min. Signals were developed using NBT/BCIP in DIG buffer 3 (100 mM Tris-HCl, 100 mM NaCl, 50 mM MgCl~2~ \[pH 9.5\]).

In vitro fertilization {#s4-4}
----------------------

After CiVP-directed induction of GVBD in late stage II follicles, ovulated oocytes and un-ovulated follicles were incubated at 20°C for an additional 24 hr in fresh ASW. The outer follicular cell layer of un-ovulated follicles was removed by pipetting. Collected oocytes were mixed with *Ciona* sperm (1.38 to 5.01 × 10^6^ cells/ml) for 10 min and washed with ASW three times. After incubation at 20°C for 16 hr, embryonic development was evaluated.

Immunofluorescence {#s4-5}
------------------

Isolated *Ciona* follicles were de-folliculated in ASW containing 0.1% collagenase and 0.1% actinase E for 1 hr with gentle agitation. After washing, the oocytes were treated with 5 μM CiVP for 0, 5, 10, 20, 40, and 60 min and fixed with 3.7% PFA in ASW at 4°C overnight. For MEK inhibition, oocytes were pretreated with 10 μM U0126 for 1 hr before CiVP stimulation. Oocytes were treated with 0.2% Triton X-100% and 0.5% blocking reagent (PerkinElmer Japan Co., Kanagawa, Japan, FP1020) and then incubated with antibody against pERK1/2 (Cell Signaling Technology \[CST\], Danvers, MA, 9101S) in Can Get Signal Immunostain Solution A (Toyobo, Osaka, Japan) for 1.5 hr and Alexa 546--conjugated anti-rabbit IgG (Thermo, A11035) for 1.5 hr. Signal was observed using a Leica M205 AF fluorescence stereomicroscope and quantified using Fiji software ([@bib61]). The specificity of the anti-pERK1/2 antibody against pCiErk1/2 was confirmed by Western blotting and immunofluorescence analyses (see below and [Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}).

Western blotting {#s4-6}
----------------

Isolated stage IV follicles were homogenized in TBS containing 1 × Complete protease inhibitor cocktail (Roche) and 1 × PhosSTOP phosphatase inhibitor cocktail (Roche). Soluble proteins were collected by two rounds of centrifugation (13,000 rpm, 10 min, 4°C), and protein concentration was determined using a Pierce BCA Protein Assay kit (Thermo). A 30 μg aliquot of soluble protein was electrophoresed, blotted onto a PVDF membrane (GE Healthcare, Buckinghamshire, UK), and blocked with Block Ace (DS Pharma Biomedical Co., Ltd., Osaka, Japan). Antibodies against ERK1/2 (1:500, CST, 9102S) and pERK1/2 (1:1000, CST, 9101S) in Can Get Signal solution were used as primary antibodies. Blocking peptide (1:200, CST, 1150S) was pre-incubated with the anti-pERK1/2 antibody to confirm the antibody's specificity. For CiCdk1, 40 μg of soluble protein extracted in 1.5 × extraction buffer (EB, 30 mM HEPES, 30 mM EGTA, 22.5 mM MgCl~2~, 1.5 mM ATP, 1.5 mM DTT, 1.5 × Complete protease inhibitor cocktail, and 1.5 × PhosSTOP phosphatase inhibitor cocktail) and p13suc1-precipitate were incubated with anti-PSTAIR primary antibody (1:1000, Abcam, ab10345) in TBS containing 0.05% Tween 20 (TBST). In the case of CiMMP2/9/13, anti--MMP-2/9/13 specific antiserum was generated (see below). Soluble *Ciona* ovary protein was homogenized in PBS. Protein secreted by the ovaries was collected from ASW after 24 hr of incubation and concentrated using Amicon Ultracel-30K centrifugal filters (Merck Millipore, Burlington, MA). A blot of 30 μg of soluble and secreted protein was blocked with Blocking One (Nacalai Tesque) and 4% normal donkey serum (Abcam, ab7475) and then incubated with anti--MMP-2/9/13 antiserum (1:3000 in Can Get Signal solution) as the primary antibody. Pre-immune serum (1:3000) or pre-absorbed antiserum (1:3000) with 70 μg of antigen was used as a negative control. After washing with TBST, the blot was incubated with the corresponding HRP-conjugated anti-mouse IgG (1:2000, GE healthcare, NA9310V) or anti-rabbit IgG (1:2000, GE Healthcare, NA9340V) secondary antibody. Signals were developed using ECL substrate (GE Healthcare).

Enrichment of CiCdk1 and in vitro activity assay {#s4-7}
------------------------------------------------

Isolated stage IV follicles were homogenized in 1.5 × EB. Soluble proteins were collected by two rounds of centrifugation (13,000 rpm, 10 min, 4°C), and the protein concentration was determined using a Bradford Protein Assay (Bio-Rad). A total of 5 μg of soluble protein was incubated overnight with 20 μl of p13suc1-sepharose at 4°C with rotation. The p13suc1-sepharose beads were kindly provided by Prof. Masakane Yamashita of Hokkaido University. After washing 3 times with 1 ml of wash buffer (20 mM HEPES, 5 mM EGTA, 15 mM MgCl~2~, 1 mM DTT, 1 × Complete protease inhibitor cocktail, 1 × PhosSTOP phosphatase inhibitor cocktail, and 0.2% Tween 20 \[pH 7.5\]), the enzymatic activity of CiCdk1 was measured using a MESACUP Cdc2/Cdk1 Kinase Assay kit (MBL, Nagoya, Japan) according to the manufacturer's instructions, with the exception that the kinase reaction was performed using sepharose with and without 1 μM Ro-3306 at 30°C for 45 min.

Preparation of recombinant CiMMP2/9/13 and antibody generation {#s4-8}
--------------------------------------------------------------

The cDNA fragment corresponding to the active form of CiMMP2/9/13 (KH.L76.4, amino acid sequence of residues 212--792) was amplified using cDNA from the ovary, Prime Star HS DNA polymerase (Takara, Shiga, Japan), and the primer pair 5'-ACAAGAGGTCCATCGTTCGG-3' and 5'-GTCGTAGTTGTCAGTGGTAG-3'. The DNA fragment was cloned into the pCR-Blunt II-TOPO vector (Thermo). DNA sequencing revealed that the insert contained a non-synonymous SNP resulting in the substitution of W with G at residue 252, which was confirmed by two independent RT-PCR analyses. In addition, 42 amino acids were inserted at residue 569: 38 amino acids were aligned with residues 569--606 of the sequence in the NCBI database (XP_009861837.1), with repetitive extension of 4 amino acids (GTGT), indicating successful cloning of the recombinant protein without any frameshifts. The *Eco*RI/*Hin*dIII fragment was inserted into the identical sites of the pET21a expression vector (Novagen, Madison, WI). Expression of rCiMMP2/9/13 was induced using the Rossetta 2 (DE3) expression system (Novagen). *Escherichia coli* cells were sonicated in 100 mM Tris-HCl (pH 7.5), and soluble proteins were removed by centrifugation. The precipitate was suspended in buffer composed of 50 mM NaH~2~PO~4~, 300 mM NaCl, and 6 M urea and solubilized by sonication. rCiMMP2/9/13 was purified with a vector-derived His-tag at the C-terminus using Ni-NTA agarose (QIAGEN, Hilden, Germany). Purified rCiMMP2/9/13 was concentrated in PBS by ultrafiltration using an Amicon Ultra-centrifugal filter (Merck, Tokyo, Japan). Purified rCiMMP2/9/13 was then injected into rabbits for immunization (Hokudo Co., Ltd., Hokkaido, Japan). The specificity of the resultant antiserum against CiMMP2/9/13 was confirmed by Western blotting ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}).

Immunohistochemistry {#s4-9}
--------------------

*Ciona* ovaries were fixed in Bouin's solution, embedded in SCEM, and sectioned at 10 μm. The resulting slides were dried at 37°C for 1 hr and washed with PBS. The samples were then boiled in 10 mM citrate buffer (pH 6.0) for 5 min using a microwave oven and cooled for 30 min at room temperature. Endogenous peroxidase activity was quenched by incubating the samples with 0.3% hydrogen peroxide for 10 min. The samples were then sequentially blocked for 30 min each with Blocking One (Nacalai Tesque) and normal horse serum of the R.T.U. VECTASTAIN Universal Elite ABC kit (Vector Laboratories, Burlingame, CA). Anti--MMP-2/9/13 antiserum was used as the primary antibody. Immunoreactivity was assessed using an ABC kit according to the manufacturer's instructions.

In vitro collagenase activity assay {#s4-10}
-----------------------------------

A total of 0.5 μg of rMMP-2/913 was incubated with 5 μg of DQ collagen type I or type IV in 200 μl of reaction buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2) in the presence or absence of 1 μM MMP-2/MMP-9 inhibitor II at 20°C. After 48 hr of incubation, the fluorescence was measured using a FlexStation II (Molecular Devices, Sunnyvale, CA) with the following settings: Ex, 485 nm; Em, 538 nm; cut-off, 495 nm.

In situ zymography {#s4-11}
------------------

Isolated late stage III follicles were incubated with 50 μg/ml of DQ collagen type I (Thermo, D12060) or DQ collagen type IV (Thermo, D12052) in ASW at 20°C for 3 hr. The follicles were then washed with ASW three times, and fluorescence was observed using a Leica M205 FA fluorescence stereomicroscope.

Statistical analysis {#s4-12}
--------------------

Results are shown as the mean ± standard error of the mean (SEM) of at least three independent experiments. Data were analyzed using the Student's *t* test for one or two pairs of samples and one-way ANOVA followed by Tukey's *post hoc* test for multiple samples using Free-JSTAT statistical software (version 22.0E, Masato Sato, Japan). Differences were considered statistically significant at p\<0.05.
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###### DEG profiles based on RNA-seq of fractionated follicles.

DEGs (upregulated (\>2 fold) or downregulated (\<0.5 fold) genes) in the indicated stages of follicles are shown in each tab. Gene ID (column A), reads mapped to the cDNA library (column B-K), RPKM (column L-U), ratio (column V-AC), UniProt ID (column AD), homologous protein (column AE), and E-value (column AF) are shown.

10.7554/eLife.49062.031

###### DEG profiles based on RNA-seq of MEK-inhibited follicles.

DEGs (upregulated (\>2 fold) or downregulated (\<0.5 fold) genes) in early stage III follicles following MEK-inhibition for 24 hr are shown. Gene ID (column A), reads mapped to the cDNA library (column B-G), RPKM (column H-M), ratio (column N-P), UniProt ID (column Q), homologous protein (column R), and E-value (column S) are shown.

10.7554/eLife.49062.032

Data availability {#s7}
=================

All data generated or analyzed in this study are included in the manuscript and supporting files. Accession numbers of RNA-seq data in this study are described in Table 1 and Table 2. All RNA seq-data are provided in Supplementary files 1 and 4.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"The regulation of oocyte maturation and ovulation in proto-vertebrates\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Marianne Bronner as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Elisabetta Tosti (Reviewer \#1); Yutaka Satou (Reviewer \#2).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This study provides significant advancement in understanding of how oocyte maturation and ovulation are controlled in an ascidian, *Ciona intestinalis*. Studying oocyte maturation and ovulation in ascidians may provide important insights into how oocyte development evolved. The reviewers are overall very positive and provided comments that can be addressed with straightforward revisions (they are provided as individual comments).

Reviewer \#1:

This paper describes the induction of maturation and ovulation by neuropeptides and the related downstream pathways involving MPF mobilization in the ascidian *Ciona robusta*. The manuscript is interesting and provides new evidences on a topic which needs still to be clarified. The experimental design is well conducted and the results are supported by a solid statistic.

I found some major points to be revised:

Abstract: reports too many literature information but poor description of the present data. Modify it accordingly.

Introduction: oocyte maturation is underlined by meiosis. Authors do not well describe the scientific background of their experimental work. An effort should be made to introduce basic concepts as: the nuclear and cytoplasmic maturation; the meiotic arrest at different stages along the species and the recognized GVBD inducers in the most studied model species. (These are poorly described in the fourth paragraph of the Discussion).

Introduction, fourth paragraph: quote Brunetti et al., 2015.

In Materials and methods authors should describe in details the anatomy of reproductive apparatus as they do in Figure 7 to let the readership understand the sequence of maturation in the ovary and ovulation in the oviduct. This is necessary to not confuse the ovulatory process with the following spawning in the sea water.

In the subsection "Western blotting", quote the temperature and quote the concentration of spermatozoa added.

In conclusion this paper is well written and adds a new contribute the knowledge of oocyte maturation trigger, meiosis resumption and the consequent ovulation in ascidians. Of importance is also the evolutionary implication due to the proved relationship between ascidians and vertebrates. I support the publication on *eLife*

Reviewer \#2:

Matsubara et al. reported how oocyte maturation and ovulation are controlled in an ascidian, *Ciona intestinalis*. First they described how oocyte maturation and ovulation proceed in a macroscopic view. Then they revealed that vasopressin, MAPK pathway, and MMP were involved in this control at the molecular level. Their success will probably be based on development of a simple but effective method to fractionate follicles, because it enabled them to do molecular biological assays. Oocyte maturation and ovulation are fundamental biological processes for animals. However, the regulatory mechanism may be very different between vertebrates and other animals. This raises a question how the vertebrate system emerged during evolution. To answer this question, the ascidian system is promising, as they indeed demonstrated. This is because ascidians are the closest invertebrate relative of vertebrates. In addition, the system they revealed in the present study may provide leads for studies in vertebrate systems, because it is possible that a similar mechanism also works in vertebrates. The experimental results shown in this manuscript was clear and sufficient for supporting their conclusions. I think that this manuscript should be published (I have no substantive concerns).

Reviewer \#3:

This paper describes experiments that demonstrate that a neuropeptide of the vasopressin/oxytocin family member in ascidians is involved in ovulation and oocyte maturation. They further implicate ERK signaling and MPF activity in these processes, and show that MMP activity may be cleaving collagen downstream of these pathways. They make a number of important technical advances, including observing ovulation in ascidians, fractionating stages of maturing oocytes by size, and localizing collagenase activity in situ.

While the results are solid, and they make considerable progress elucidating the mechanisms of ovulation and maturation in this species, the main conclusions do not make clear, broad implications, and thus read like an incremental advance. They will likely be of limited interest for most readers of *eLife*.

The impact of the work could be enhanced by framing the results in a more general way, and making the evolutionary implications more explicit. The origin of the HPG axis in vertebrates is an important vertebrate innovation. In principle, the results presented here could add to our understanding of its origin, by helping to establish the likely ancestral character state at the base of the vertebrates. From this perspective, it would help if they were clearer about how their findings relate to what has been found in other invertebrates. Do other invertebrates have VP/OT-type peptides? Are the neuropeptides that have been implicated in oocyte maturation in other invertebrates similar in any way to peptide and receptor implicated here? It seems like more can be said about what their work tells us about metazoan oocyte maturation in general.

Similarly, they need to be clearer about how their results relate to what is known in vertebrates. It is very interesting that fish use a VP-related gene for oocyte maturation and ovulation, and this suggests a hypothesis about how their data relates to vertebrates, as they point out. However, this argument could be made more directly. They point out that mouse VP receptor genes are expressed in the ovary, but they do not state whether existing functional studies of VP in mouse would have revealed a role in this organ; it would help to add this if it is true and if they are implying that such a role might exist.

As an aside, is the fish vasotocin peptide similarly related to vasopressin and oxytocin in mammals? Might it represent the ancestral gene these two peptides in mammals? Again, clarification of the distribution of vasopressin and oxytocin peptides across animals might help make the story clearer.

10.7554/eLife.49062.035

Author response

Reviewer \#1:

> \[...\] I found some major points to be revised:
>
> Abstract: reports too many literature information but poor description of the present data. Modify it accordingly.

We have revised the Abstract to better describe our data, as indicated below. In addition, please note that the word "proto-vertebrate" and the phrase "conserved prototypic regulatory systems" have been removed in the revised version.

"Ascidians are the closest living relatives of vertebrates, and their study is important for understanding the evolutionary processes of oocyte maturation and ovulation. \[...\] This is the first demonstration of essential pathways regulating oocyte maturation and ovulation in ascidians and will facilitate investigations of the evolutionary process of peptidergic regulation of oocyte maturation and ovulation throughout the phylum Chordata."

> Introduction: oocyte maturation is underlined by meiosis. Authors do not well describe the scientific background of their experimental work. An effort should be made to introduce basic concepts as: the nuclear and cytoplasmic maturation; the meiotic arrest at different stages along the species and the recognized GVBD inducers in the most studied model species. (These are poorly described in the fourth paragraph of the Discussion).

Thank you for your constructive suggestion. In the Introduction section of the revised version, we have described in greater detail the background of oocyte maturation in relation to nuclear and cytoplasmic maturation, the species-specific stage of second meiotic arrest, inducers of oocyte maturation/ovulation in other invertebrates, and the similar and unique properties of the molecular mechanism underlying GVBD induction between *Ciona* and other animals.

"Meiosis in animal oocytes is arrested at prophase of the first division (ProI). Hormonal stimulation triggers the resumption of meiosis in most vertebrates and invertebrates, and oocytes undergo nuclear maturation upon the onset of nuclear disassembly (i.e., germinal vesicle breakdown \[GVBD\]). \[...\] Mature oocytes are then ovulated via proteolytic degradation of the follicle walls (Richards and Ascoli, 2018; Takahashi et al., 2018; Richards and Pangas, 2010)."

> Introduction, fourth paragraph: quote Brunetti et al., 2015.

We have cited Brunetti et al., 2015 in the reference list.

> In Materials and methods authors should describe in details the anatomy of reproductive apparatus as they do in Figure 7 to let the readership understand the sequence of maturation in the ovary and ovulation in the oviduct. This is necessary to not confuse the ovulatory process with the following spawning in the sea water.

Thank you for your comments. We have illustrated the anatomic structure of the *Ciona* ovary in revised Figure 7A and B, and we have added appropriate explanations in the Materials and methods section.

"Mature oocytes in the ovary are extruded into the ovarian tube (ovulated) and stored in the oviduct until spawning (Figure 7A and B, Sugino et al., 1990; Kawamura et al., 2011)."

> In the subsection "Western blotting", quote the temperature and quote the concentration of spermatozoa added.

We have added the temperature of follicle/embryo incubation and the number of spermatozoa in IVF, as follows:

"After CiVP-directed induction of GVBD in late stage II follicles, ovulated oocytes and un-ovulated follicles were incubated at 20°C for an additional 24 h in fresh ASW. \[...\] After incubation at 20°C for 16 h, embryonic development was evaluated."

> In conclusion this paper is well written and adds a new contribute the knowledge of oocyte maturation trigger, meiosis resumption and the consequent ovulation in ascidians. Of importance is also the evolutionary implication due to the proved relationship between ascidians and vertebrates. I support the publication on eLife

Reviewer \#3:

> \[...\] While the results are solid, and they make considerable progress elucidating the mechanisms of ovulation and maturation in this species, the main conclusions do not make clear, broad implications, and thus read like an incremental advance. They will likely be of limited interest for most readers of eLife.
>
> The impact of the work could be enhanced by framing the results in a more general way, and making the evolutionary implications more explicit. The origin of the HPG axis in vertebrates is an important vertebrate innovation. In principle, the results presented here could add to our understanding of its origin, by helping to establish the likely ancestral character state at the base of the vertebrates. From this perspective, it would help if they were clearer about how their findings relate to what has been found in other invertebrates. Do other invertebrates have VP/OT-type peptides? Are the neuropeptides that have been implicated in oocyte maturation in other invertebrates similar in any way to peptide and receptor implicated here? It seems like more can be said about what their work tells us about metazoan oocyte maturation in general.

Thank you for your constructive comments. First, we address the reviewer's question. VP/OT family peptides are conserved in vertebrates and many invertebrates, including ascidians, amphioxus, echinoderms, annelids, molluscs, and nematodes. Moreover, some insects (e.g., red beetles) possess a VP/OT family peptide, whereas other insects (e.g., fruit flies) lack such peptides (Banerjee et al., 2017; Stoop, 2012; Donaldoson and Young, 2008). These peptides, with some exceptions, completely share Cys^1^, Asn^5^, Cys^6^, Pro^7^, and Gly^9^. In mammals, VP and OT are classified based on the amino acid residue present at position 8; the VP family peptides contain a basic amino acid, and the OT family peptides contain a neutral amino acid at this position. The respective homologs are conserved in non-mammalian vertebrates. Non-mammalian vertebrate VP homologs are designated as vasotocin (VT). Moreover, non-mammalian tetrapod and fish OT homologs are designated mesotocin (MT) and isotocin (IT), respectively. Notably, only VT is present in the lowest vertebrate agnathans. Most invertebrates also possess a single VP/OT family peptide. In addition, some invertebrate VP/OT family peptides harbor a basic amino acid, whereas others harbor a non-basic amino acid. On the other hand, the structural organization is conserved in all precursors of VP/OT family peptides: a signal peptide region, a single VP/OT family peptide sequence, and a neurophysin domain that features multiple cysteines (Banerjee et al., 2017; Stoop, 2012; Donaldson and Young, 2008). Collectively, VP/OT family peptides are thought to have emerged in an ancestral stem group of vertebrates and invertebrates \~600 million years ago (Banerjee et al., 2017; Stoop, 2012; Donaldoson and Young, 2008), leading to the occurrence of the VP and OT family during the evolution of gnathostomates via gene duplication, while classification of invertebrate VP/OT family peptides into the VP or OT family on the basis of the residue at position 8 is impossible (Banerjee et al., 2017; Stoop, 2012; Donaldson and Young, 2008).

Next, we address the question regarding the biological roles of VP/OT family peptides and the regulation of oocyte maturation and ovulation by peptides. To date, multiple biological functions of these peptides have been reported in various organisms. However, the present paper shows for the first time that an OT/VP family peptide regulates oocyte maturation and ovulation in an organism, as described in the original manuscript. Instead, a few species-specific peptides have been shown to be responsible for oocyte maturation and ovulation in other invertebrates such as jellyfish, starfish, and sea cucumber, and thus, we mentioned them in the Introduction and Discussion sections of the revised manuscript, indicating that inducible factors and the molecular mechanisms underlying oocyte maturation and ovulation vary among invertebrate species. Additionally, in jellyfish, direct induction of oocytes by MIH (Takeda et al., 2018) is similar to the direct activity of CiVP on oocytes rather than the two-step induction by starfish relaxin-like peptide via 1-methyladenosine (a direct inducer of oocyte maturation and ovulation in starfish) produced in and secreted from follicular cells (Mita et al., 2009). These points have also been included in the revised manuscript, as shown below:

In the Introduction section:

"The neuropeptide W/RPRPamide in jellyfish directly induces oocyte maturation and spawning (Takeda et al., 2018). \[...\] These findings demonstrate that various neuropeptides are responsible for triggering oocyte maturation and ovulation in invertebrates, and suggest that oocyte maturation and ovulation and their underlying molecular mechanisms are regulated in both a species-specific and evolutionarily conserved fashion."

In the Discussion section:

"The vertebrate OT and VP families are thought to have emerged from a common ancestral gene via gene duplication during the evolution of gnathostomates, and invertebrates and jawless vertebrates have been shown to possess a single VP/OT family peptide (Banerjee et al., 2017; Stoop, 2012; Donaldoson and Young, 2008). \[...\] VT was also reported to be involved in oocyte maturation and ovulation in catfish (Singh and Joy, 2011; Joy and Chaube, 2015)."

> Similarly, they need to be clearer about how their results relate to what is known in vertebrates. It is very interesting that fish use a VP-related gene for oocyte maturation and ovulation, and this suggests a hypothesis about how their data relates to vertebrates, as they point out. However, this argument could be made more directly. They point out that mouse VP receptor genes are expressed in the ovary, but they do not state whether existing functional studies of VP in mouse would have revealed a role in this organ; it would help to add this if it is true and if they are implying that such a role might exist.

As described in the original manuscript, VT, the fish VP homolog, was shown to be involved in oocyte maturation and ovulation. This is the only previous study demonstrating the activity of VP/OT family peptides in induction of oocyte maturation and ovulation. However, as stated in the original version as well, we have verified that the regulation of oocyte maturation and ovulation via CiVP is distinct from that mediated by catfish VT. In addition, animals genetically deficient in VPR and OTR were generated, but no phenotypic defects in oocyte maturation and ovulation have been reported. Considering these previous findings and the present data, we rephrased the corresponding text in the Discussion section, as shown below:

"However, VT-induced oocyte maturation and ovulation are mediated primarily via the VT receptor in follicular cells and following sexual steroidogenesis (Singh and Joy, 2011; Joy and Chaube, 2015; Rewat et al., 2018). \[...\] Consequently, elucidating the biological roles of VP/OT family peptides in the ovary and in the process of VPergic oocyte maturation and ovulation evolution awaits further investigations."

> As an aside, is the fish vasotocin peptide similarly related to vasopressin and oxytocin in mammals? Might it represent the ancestral gene these two peptides in mammals? Again, clarification of the distribution of vasopressin and oxytocin peptides across animals might help make the story clearer.

As described in the original manuscript, VT, the fish VP homolog, was shown to be involved in oocyte maturation and ovulation. This is the only previous study demonstrating the activity of VP/OT family peptides in induction of oocyte maturation and ovulation. However, as stated in the original version as well, we have verified that the regulation of oocyte maturation and ovulation via CiVP is distinct from that mediated by catfish VT. In addition, animals genetically deficient in VPR and OTR were generated, but no phenotypic defects in oocyte maturation and ovulation have been reported. Considering these previous findings and the present data, we rephrased the corresponding text in the Discussion section, as shown below:

"However, VT-induced oocyte maturation and ovulation are mediated primarily via the VT receptor in follicular cells and following sexual steroidogenesis (Singh and Joy, 2011; Joy and Chaube, 2015; Rewat et al., 2018). \[...\] Consequently, elucidating the biological roles of VP/OT family peptides in the ovary and in the process of VPergic oocyte maturation and ovulation evolution awaits further investigations."

[^1]: Suntory Foundation for Life Sciences, Kyoto, Japan.
